Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis.

BACKGROUND Comparing the dose-response of a new drug to that of a previously studied drug can aid in understanding their relative potencies. Two dose-finding studies addressed the effect of a new drug, rosuvastatin, on its ability to decrease low-density lipoprotein cholesterol (LDL-C) levels. One of these studies included 2 doses of atorvastatin, and substantial additional information is available in the literature about the effect of atorvastatin on LDL-C level lowering. METHODS The 2 dose-finding studies of rosuvastatin considered otherwise healthy patients who had hypercholesterolemia. Comparable studies of atorvastatin were identified via a MEDLINE search in December 1999. Multiple reviewer consensus identified 15 of 41 studies on atorvastatin published since 1996 that met these selection criteria: reporting of LDL-C level change from baseline at least 6 weeks after treatment initiation, doses administered, and treatment group sizes. Eligible populations had clinical evidence of hypercholesterolemia. We excluded studies with patients who had severe illness or a previous history of transplantation. Data extraction of the mean, sample sizes, and SDs (or CIs) by dose was carried out independently by multiple reviewers. We combined the results from the various studies with Bayesian hierarchical modeling and analyzed them with Markov chain Monte Carlo techniques. RESULTS Combining this study and literature results substantially increased the power to compare the dose-response relationships of rosuvastatin and atorvastatin. Rosuvastatin reduced LDL-C level by an estimated 10 to 17 percentage points more than atorvastatin when both were given at the same dose. Approximately one quarter of the dose of rosuvastatin achieved about the same magnitude of LDL-C level reduction as atorvastatin at dosages as high as 80 mg. This finding does not imply a 4-fold difference in efficacy overall and specifically does not describe the results at higher dosage levels. CONCLUSIONS Bayesian meta-analysis of results from related studies allows the comparison of the dose-response relationships of 2 drugs, better estimates of a particular dose-response relationship within an individual study, and the expression of relative benefits (of dose and drug) in terms of probabilities. Explicitly comparing a study's results with historical data using Bayesian meta-analysis allows clinicians to view the study in the larger context of medical research.

[1]  J. Mckenney,et al.  Atorvastatin, a New HMG-CoA Reductase Inhibitor as Monotherapy and Combined With Colestipol , 1996, Journal of cardiovascular pharmacology and therapeutics.

[2]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[3]  R. Knopp.  Drug treatment of lipid disorders. , 1999, The New England journal of medicine.

[4]  D. Hunninghake,et al.  Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) , 1998, The American journal of cardiology.

[5]  S. Goodman.  Toward Evidence-Based Medical Statistics. 1: The P Value Fallacy , 1999, Annals of Internal Medicine.

[6]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[7]  J. Mckenney,et al.  A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group. , 1998, The American journal of medicine.

[8]  D. Berry,et al.  Benefits and risks of screening mammography for women in their forties: a statistical appraisal. , 1998, Journal of the National Cancer Institute.

[9]  A. Olsson,et al.  Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. , 2001, The American journal of cardiology.

[10]  David B. Dunson,et al.  Bayesian Data Analysis , 2010 .

[11]  E. Liberopoulos,et al.  Comparison of the Efficacy of Atorvastatin and Micronized Fenofibrate in the Treatment of Mixed Hyperlipidemia , 1999, Journal of cardiovascular risk.

[12]  W. März,et al.  Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial). , 1999, The American journal of cardiology.

[13]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[14]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[15]  C. Sirtori,et al.  Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. , 1997, Atherosclerosis.

[16]  S L George,et al.  Stopping a clinical trial early: frequentist and Bayesian approaches applied to a CALGB trial in non-small-cell lung cancer. , 1994, Statistics in medicine.

[17]  D. Waters,et al.  Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. , 1999, The New England journal of medicine.

[18]  G. Jerums,et al.  A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia , 1997 .

[19]  S M Berry.  Understanding and testing for heterogeneity across 2 x 2 tables: application to meta-analysis. , 1998, Statistics in medicine.

[20]  J. Isaacsohn,et al.  Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. , 1996, JAMA.

[21]  William DuMouchel,et al.  Computer-modeling and Graphical Strategies for Meta-analysis , 2000 .

[22]  S. Goodman,et al.  Toward Evidence-Based Medical Statistics. 2: The Bayes Factor , 1999, Annals of Internal Medicine.

[23]  Donald A. Berry,et al.  Meta-Analysis in Medicine and Health Policy , 2000 .

[24]  L. Joseph,et al.  Placing trials in context using Bayesian analysis. GUSTO revisited by Reverend Bayes. , 1995, JAMA.

[25]  D. Sprecher,et al.  Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[26]  D K Stangl,et al.  Prediction and decision making using Bayesian hierarchical models. , 1995, Statistics in medicine.

[27]  D. Lindley,et al.  Bayes Estimates for the Linear Model , 1972 .

[28]  Donald A. Berry,et al.  Statistical Methodology in the Pharmaceutical Sciences , 1989 .

[29]  A. Sorisky,et al.  Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[30]  Donald A. Berry,et al.  Meta-analysis: Past and Present Challenges , 2000 .

[31]  Daniel T. Larose,et al.  Grouped random effects models for Bayesian meta-analysis. , 1997, Statistics in medicine.

[32]  J. Mckenney,et al.  Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. , 1997, The American journal of cardiology.

[33]  Patrick D. Larkey,et al.  Bridging Different Eras in Sports , 1999 .

[34]  J. Mckenney,et al.  The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. , 1996, Clinical therapeutics.

[35]  A. Gotto,et al.  Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. , 2002, The American journal of cardiology.

[36]  J C Wakefield,et al.  Hierarchical models for multicentre binary response studies. , 1990, Statistics in medicine.

[37]  L. Shurzinske,et al.  Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels. , 1997, Atherosclerosis.

[38]  Donald A. Berry,et al.  Statistics: A Bayesian Perspective , 1995 .

[39]  J. Berger.  Statistical Decision Theory and Bayesian Analysis , 1988 .

[40]  M. Linton,et al.  Current perspectives on statins. , 2000, Circulation.

[41]  J. Crouse,et al.  Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. , 1999, The American journal of cardiology.

[42]  B J Biggerstaff,et al.  Bayesian meta-analysis, with application to studies of ETS and lung cancer. , 1996, Lung cancer.

[43]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.